July 27, 2017 5:22 AM ET

Pharmaceuticals

Company Overview of Lycera Corp.

Company Overview

Lycera Corp., a biopharmaceutical company, develops oral immune modulators for the treatment of patients with autoimmune diseases and cancer. Its product pipeline includes LYC-30937, an ATPase modulator for the treatment of inflammatory bowel disease; oral RORgamma agonists for diverse applications in immune-oncology; and Rho kinase inhibitors, histone deacetylase 6 inhibitors, RORgt antagonists, and collaboration targets. Lycera Corp. was founded in 2006 and is headquartered in Ann Arbor, Michigan.

2800 Plymouth Road

NCRC

Building 26

Ann Arbor, MI 48109

United States

Founded in 2006

Phone:

734-233-3060

Key Executives for Lycera Corp.

Chief Executive Officer, President and Director
Age: 59
Co-Owner
Chief Financial Officer
Senior Vice President of Biology
Chief Medical Officer
Compensation as of Fiscal Year 2017.

Lycera Corp. Key Developments

Lycera Corp. Presents at BIO International Conference 2017, Jun-19-2017 02:30 PM

Lycera Corp. Presents at BIO International Conference 2017, Jun-19-2017 02:30 PM. Venue: San Diego Convention Center, San Diego, CA 2865, United States. Speakers: Paul J. Sekhri, Chief Executive Officer, President and Director.

Lycera Corp. Announces Board Changes

Lycera Corp. announced that Pablo J. Cagnoni, M.D., has been elected to the company's Board of Directors, effective immediately. The company also announced that Timothy M. Mayleben will step down from his position on Lycera's Board. Dr. Cagnoni is President and Chief Executive Officer of Tizona Therapeutics.

Lycera Corp. Announces Initiation of Phase 1/2a Study Argon of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors

Lycera Corp. announced the initiation of a Phase 1/2a clinical trial of the company's novel immuno-oncology therapeutic candidate LYC-55716, in patients with advanced, relapsed, or refractory solid tumors. The ARGON trial (Trial of RORgamma Agonist LYC-55716 in Advanced Cancer) is a Phase 1/2a study of LYC-55716 in patients with advanced, relapsed or refractory solid tumors. The initial Phase 1 portion of the study is designed to find the biologically active or maximum tolerated dose of LYC-55716. The study will utilize a 3+3 study design, in which LYC-55716 will be administered orally in subjects with relapsed or refractory solid tumors. The primary endpoints are safety and tolerability, and the study is designed to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose. Upon dose determination, LYC-55716 will enter Phase 2a, which is expected to enroll approximately 40 patients. The primary efficacy endpoint of the Phase 2a portion of the study will be objective response rate according to response evaluation criteria in solid tumors.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Lycera Corp., please visit www.lycera.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.